| Target Price | ¥1,377.00 |
| Price | ¥1,216.50 |
| Potential |
13.19%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target SHO-BOND 2027 .
The average SHO-BOND target price is ¥1,377.00.
This is
13.19%
register free of charge
¥1,816.50
49.32%
register free of charge
¥1,060.50
12.82%
register free of charge
|
|
| A rating was issued by 7 analysts: 4 Analysts recommend SHO-BOND to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the SHO-BOND stock has an average upside potential 2027 of
13.19%
register free of charge
|
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 89.20 | 92.01 |
| 1.66% | 3.15% | |
| EBITDA Margin | 24.17% | 23.85% |
| 1.87% | 1.32% | |
| Net Margin | 17.31% | 16.40% |
| 4.24% | 5.24% |
5 Analysts have issued a sales forecast SHO-BOND 2027 . The average SHO-BOND sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an SHO-BOND EBITDA forecast 2027. The average SHO-BOND EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 SHO-BOND Analysts have issued a net profit forecast 2027. The average SHO-BOND net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 76.07 | 75.27 |
| 4.19% | 1.05% | |
| P/E | 16.24 | |
| EV/Sales | 2.47 |
4 Analysts have issued a SHO-BOND forecast for earnings per share. The average SHO-BOND EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


